Researchers' Work from University of Alabama at Birmingham Focuses on Idiopathic Pulmonary Fibrosis (Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of...).
In: Immunotherapy Weekly, 2024-04-09, S. 529-529
serialPeriodical
Zugriff:
Researchers from the University of Alabama at Birmingham have designed a clinical trial called STRIVE-IPF to determine the efficacy of combined therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG) for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). AE-IPF is a serious complication of idiopathic pulmonary fibrosis (IPF) with limited treatment options and high mortality. The trial aims to assess the six-month survival rate as the primary endpoint, as well as secondary endpoints such as oxygen requirement and six-minute walk distance. The experimental therapy in this trial has the potential to significantly impact the treatment of AE-IPF. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers' Work from University of Alabama at Birmingham Focuses on Idiopathic Pulmonary Fibrosis (Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of...).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-04-09, S. 529-529 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Sonstiges: |
|